href:https://www.businesswire.com/news/home/20220224005528/en/Sequence-Based-AI-Driven-Drug-Discovery-Company-Deargen-Raises-US17-Million-in-SeriesB-Financing-Round-to-Accelerate-In-House-Pipeline

Sequence Based, AI-Driven Drug Discovery Company, Deargen Raises US$17 Million in SeriesB Financing Round to Accelerate In-House Pipeline

Will establish a 2,600m2 AI convergence new drug development center (iDear Center) and accelerate internal new drug development